BioNTech SE is 3.4x more valuable than Immunovant, Inc. by market capitalization ($21.79 B vs $6.40 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IMVT | BNTX |
|---|---|---|
| Market cap | $6.40 B | $21.79 B |
| US-listed rank | #1219 | #587 |
| Net income (latest FY) | -$505.61M | - |
| SEC filings | 611 | 548 |
BioNTech SE is 3.4x more valuable than Immunovant, Inc. by market capitalization ($21.79 B vs $6.40 B).
Full pages: Immunovant, Inc. and BioNTech SE, or browse the full rankings.